LGVN

Longeveron Inc. Class A · NASDAQ

Sector Health Technology
Industry Biotechnology
Website longeveron.com
Employees(FY) 19
ISIN US54303L2034

Performance

-9.13%

-9.57%

-26.17%

+58.82%

+38.97%

YTD

-0.53%

Profile

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, a candidate in Phase 2a/b trials that is used for the treatment of alzheimer's disease, hypoplastic left heart syndrome, and aging-related frailty. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Advanced Technical Analysis

Technical Analysis of LGVN 2024-11-22

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 23 indicating strong downward pressure, while the Oscillators Score of 53 suggests a neutral stance. Overall, the Technical Score of 38 reinforces the bearish outlook, signaling caution for potential investors.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of LGVN

Stock Rank

Recent News & Updates

2024-11-12 03:05
Longeveron Announces Third Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-11-10 20:05
Longeveron Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)(Globenewswire)
2024-11-04 03:05
Longeveron to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024(Globenewswire)
2024-10-28 22:00
Longeveron Presents Lomecel-B Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)(Globenewswire)
2024-10-27 03:10
Longeveron Presents Lomecel-B Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting(Globenewswire)
2024-10-13 21:05
Longeveron Lomecel-B Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)(Globenewswire)
2024-10-08 21:05
Longeveron Lomecel-B 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual Meeting(Globenewswire)
2024-10-06 21:05
Longeveron to Present at the UBS Virtual Organ Restoration and Cell Therapy Day(Globenewswire)
2024-10-01 21:05
Longeveron to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference(Globenewswire)
2024-09-25 21:05
Longeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the Mesa(Globenewswire)
2024-09-02 21:00
Longeveron Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS)(Globenewswire)
2024-08-26 04:05
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-14 04:05
Longeveron Announces Second Quarter 2024 Financial Results and Provides Business Update(Globenewswire)
2024-08-05 04:05
Longeveron to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024(Globenewswire)
2024-07-28 04:51
Longeveron Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B in Mild Alzheimer's Disease at the Alzheimer's Association International Conference (AAIC)(Globenewswire)
2024-07-19 04:05
Longeveron Announces Closing of $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-17 20:45
Longeveron Announces $9.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules(Globenewswire)
2024-07-16 20:00
Longeveron Announces U.S. FDA Grants Fast Track Designation for Lomecel-B for the Treatment of Mild Alzheimer's Disease(Globenewswire)
2024-07-10 00:08
PLUG Stock: Plug Power Shares Hydrogen Refueling Station Update(Investorplace)
2024-07-09 23:34
Why Is Longeveron (LGVN) Stock Up 53% Today?(Investorplace)
2024-07-09 19:30
Longeveron Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease(Globenewswire)
2024-07-08 21:00
Neha Motwani Elected to Longeveron Board of Directors(Globenewswire)
2024-07-07 21:00
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron Board of Directors(Globenewswire)
2024-06-20 20:35
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing(Yahoo Finance)
2024-06-18 22:30
3 Penny Stocks Poised to Turn Pocket Change Into a Small Fortune by 2028(Investorplace)
2024-06-18 04:48
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Exercise Transaction(Globenewswire)
2024-06-17 20:35
Life Sciences Virtual Investor Forum Agenda Announced for June 20th(Yahoo Finance)
2024-06-16 21:45
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase(Globenewswire)
2024-06-16 21:00
Longeveron to Present at the Virtual Life Sciences Investor Forum on June 20, 2024(Globenewswire)
2024-06-16 20:38
Longeveron Announces Exercise of Warrants for $4.4 Million Gross Proceeds(Globenewswire)

Page 1 of 6

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.